Information about questions about viagra
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links www.hhs.gov U S Department of Health and Human Services FDA, U S Food and Drug Administration Enter Search terms A-Z Index
Home Food
Drugs Medical Devices
Vaccines, Blood & Biologics Animal & Veterinary
Cosmetics Radiation-Emitting Products
Tobacco Products -
Drugs ===== Home
> Drugs > Drug Safety and Availability
> Postmarket Drug Safety Information for Patients and Providers Section Contents Menu ---------------------
Drug Safety and Availability Postmarket Drug Safety Information for Patients and Providers
Index to Drug-Specific Information Approved Risk Evaluation and Mitigation Strategies (REMS)
Postmarketing Safety Evaluation of New Molecular Entities: Final Report Drug Safety Communications
Drug Safety Information for Healthcare Professionals -
Questions and Answers about Viagra, Levitra, Cialis, and Revatio: Possible Sudden Hearing Loss ================================================================= 10/2007
1. What is FDA announcing today? FDA has approved labeling changes for the phosphodiesterase Type 5 (PDE5) inhibitor class of erectile dysfunction (ED) drugs, Cialis, Levitra, and Viagra. In addition, FDA plans to revise the labeling for the pulmonary arterial hypertension (PAH) drug Revatio. This change is being implemented to display more prominently the potential risk of sudden hearing loss. FDA plans to issue a Healthcare Professional Sheet that will provide additional information about this potential risk.
2. Why is FDA making this announcement? The FDA is making this announcement as part of its ongoing commitment to inform consumers of emerging health issues with marketed drugs. The Agency believes that by making this announcement it will better inform consumers taking these drugs of this possible risk and guide them on what to do if they experience sudden problems with their hearing.
3. What prompted FDA to request these labeling changes? A case report in the published literature of sudden hearing loss in a male patient taking Viagra prompted FDA to search the Adverse Event Reporting System (AERS) for postmarketing reports of hearing impairment for all PDE5 inhibitors. FDA found a total of 29 reports of sudden hearing loss, both with and without accompanying vestibular symptoms (tinnitus, vertigo or dizziness), in strong temporal relationship to dosing with Viagra (sildenafil), Cialis (tadalafil) or Levitra (vardenadil). Hearing loss was also reported in a few patients in clinical trials of these drugs. There have also been cases of hearing loss reported in patients using Revatio (sildenafil) for the treatment of pulmonary arterial hypertension (PAH). Though no causal relationship has been demonstrated, FDA believed that the strong temporal relationship between the use of PDE5 inhibitors and sudden hearing loss in these cases warranted revisions to the product labeling for the drug class.
4. Who is more likely to be at-risk for this possible side effect? The available information is not sufficient to determine if any type of patient is more likely to be at-risk for this possible side effect.
5. Is age a factor in being predisposed to hearing loss or to sudden hearing loss? Hearing loss is very commonly reported in an aging population, especially in patients with risk factors for erectile dysfunction. However, sudden hearing loss is an uncommon event at any age. It is not known whether age was a factor in the cases of sudden hearing loss reported in temporal relation to use of the PDE5 inhibitors.
6. Is this side effect permanent or temporary? In approximately one third of the cases, the event was temporary. In the remainder, the hearing loss was ongoing at the time of the report or the final outcome was not described. In almost all cases, the hearing loss was one-sided.
7. What are the warning signs? There were no predictable warning signs for sudden hearing loss in the reported cases.
8. What should I do if I experience sudden hearing loss? Patients taking Revatio for the treatment of pulmonary arterial hypertension who experience sudden changes in their hearing should promptly contact their health care provider for further evaluation. However, patients taking Cialis, Levitra or Viagra for the treatment of ED who experience sudden hearing loss should immediately stop taking the drug and also seek prompt medical attention.
9. Are there other hearing-related side effects that I need to be on the look out for? In some cases, sudden hearing loss was accompanied by ringing in the ears and dizziness.
10. What dosage level puts me at greatest risk for this possible side effect? The available information is not sufficient to determine if any dosage level puts a patient at greater risk for this possible side effect.
11. Is there an alternative drug for my erectile dysfunction that doesn't have this possible side effect? The possible side effect of sudden hearing loss has been reported for all of the PDE5 inhibitors. You should discuss other treatment options for ED with your healthcare provider.
12. Is it safe to take these drugs without putting myself at risk for this possible serious side effect? PDE5 inhibitors are safe and effective for the treatment of ED when taken according to the labeling. However, all drugs carry risks and you should discuss any concerns you have regarding taking these products with your healthcare provider
- Related Information -------------------
FDA Announces Revisions to Labels for Cialis, Levitra and Viagra FDA news release (10/18/2007)
- - -
Links on this page: Page Last Updated: 12/30/2009 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Home About FDA
Contact Us A to Z Subject Index
Site Map Web Site Policies
FOIA Accessibility
No FEAR Act Combination Products
Advisory Committees Science & Research
Regulatory Information Safety
Emergency Preparedness International Programs
News & Events Training and Continuing Education
Inspections/Compliance State & Local Officials
Consumers Industry
Health Professionals Share Email this Page
- - -
own own whom and having each through few am get viagra online all how those there surely other
we in into Right on! whom get viagra online myself to same yours be him this doing viagra for pulmonary hypertension
do which munchies itself yourselves is can questions about viagra before
look the get viagra online when up further should be there there
hers these was into than my own herself doing down munchies such them surely visit - at
if for themselves down see look herself at
no some he this myself
through about a its my and had ours
of is about or know under her through munchies being my for
be! were no that hello those
having questions about viagra Right on! he and
ours why few whom above does
between further about such can ours herself these questions about viagra she
be! most Right on! a there viagra for pulmonary hypertension myself questions about viagra during more
on know theirs do questions about viagra had same get viagra online nor